Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989
- PMID: 1651757
- DOI: 10.1111/j.1471-0528.1991.tb10369.x
Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989
Abstract
Objective: To assess the efficacy, toxicity and survival in patients with high risk GTT treated with the EMA/CO regimen (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine/oncovine).
Design: Open non-randomized study of 148 consecutive patients referred to the Charing Cross Hospital between 1979 and 1989.
Setting: Trophoblastic disease centre in a London teaching hospital.
Subjects: 148 consecutive patients with high risk GTT were treated with the EMA/CO regimen. 76 patients had received no prior chemotherapy and 72 had received prior chemotherapy.
Main outcome measures: Survival, causes of treatment failure and toxicity were analysed.
Results: Of 76 patients who had received no prior chemotherapy, 62 (82%) are in remission; an overall survival of 85% for the 148 patients. Ten of the 76 patients without prior chemotherapy died from extensive disease within 3 weeks of starting chemotherapy. The complete and partial response rates to EMA/CO chemotherapy were 80% and 18% respectively. The addition of cisplatin salvaged 9 of 11 (82%) who developed drug resistance and did not require surgery. Salvage surgery alone resulted in 7 of 8 (87%) having complete remissions. Relapse after EMA/CO chemotherapy is uncommon (5.4%) but survival is still relatively good with further chemotherapy and/or surgery with 6 (75%) of 8 patients obtaining a further sustained remission. Complications from EMA/CO chemotherapy are acceptable with myelosuppression being dose-limiting. Late sequelae are uncommon: menstruation usually returns with a few months, and no fetal abnormalities have been recorded in subsequent pregnancies. One patient developed what we presume to be a therapy-induced acute myeloid leukaemia.
Conclusion: At present EMA/CO chemotherapy is our treatment of choice for patients with high risk GTT. Its toxicity is predictable and reversible. In patients developing drug resistance, salvage surgery is important. Future developments may include further dose intensification with the addition of haemopoietic growth factors, earlier diagnosis and the separation of gestational from non-gestational trophoblastic tumours.
Similar articles
-
Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.J Clin Oncol. 2000 Feb;18(4):854-9. doi: 10.1200/JCO.2000.18.4.854. J Clin Oncol. 2000. PMID: 10673528
-
Management of resistant gestational trophoblastic tumors.J Reprod Med. 1998 Feb;43(2):111-8. J Reprod Med. 1998. PMID: 9513872
-
Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia.Int J Gynecol Cancer. 2006 May-Jun;16(3):1432-8. doi: 10.1111/j.1525-1438.2006.00606.x. Int J Gynecol Cancer. 2006. PMID: 16803542
-
Management of high-risk gestational trophoblastic disease.J Reprod Med. 1998 Jan;43(1):44-52. J Reprod Med. 1998. PMID: 9475149 Review.
-
Secondary chemotherapy for high-risk gestational trophoblastic neoplasia.Gynecol Oncol. 2005 May;97(2):618-23. doi: 10.1016/j.ygyno.2005.02.004. Gynecol Oncol. 2005. PMID: 15863169 Review.
Cited by
-
Hydatidiform Mole in a Patient With a Concern for Neoplasia: A Case Report.Cureus. 2020 Sep 8;12(9):e10319. doi: 10.7759/cureus.10319. Cureus. 2020. PMID: 33052280 Free PMC article.
-
Gestational trophoblastic neoplasia, management as per risk stratification in a developing country.Indian J Med Paediatr Oncol. 2016 Jan-Mar;37(1):28-31. doi: 10.4103/0971-5851.177012. Indian J Med Paediatr Oncol. 2016. PMID: 27051154 Free PMC article.
-
Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.Br J Cancer. 2000 May;82(9):1547-52. doi: 10.1054/bjoc.2000.1176. Br J Cancer. 2000. PMID: 10789722 Free PMC article.
-
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?Gynecol Oncol. 2017 Jan;144(1):125-129. doi: 10.1016/j.ygyno.2016.10.038. Epub 2016 Nov 3. Gynecol Oncol. 2017. PMID: 27816248 Free PMC article.
-
Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide.World J Clin Oncol. 2019 Feb 24;10(2):28-37. doi: 10.5306/wjco.v10.i2.28. World J Clin Oncol. 2019. PMID: 30815369 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Medical
Research Materials